Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Listed as NCT05681780, this PHASE1 trial focuses on Non Small Cell Lung Cancer and Recurrent Non Small Cell Lung Cancer and remains ongoing. Sponsored by H. Lee Moffitt Cancer Center and Research Institute, it has been updated 12 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE1
Phase: PHASE1/PHASE2 → PHASE1
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 7 earlier versions
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lee Moffitt Cancer Center and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .